Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 5Tumor-Agnostic 4Plasma cell 4Genitourinary 4Sarcoma 3Thoracic 2Lymphoid 2Other hematologic neoplasm 1Breast 1

Conditions

Neoplasms 4

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × perifosine × Tumor-Agnostic × Clear all
NCT01224730 2018-03-14

A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies

AEterna Zentaris

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

NCT00398697 2014-02-13

Phase I Perifosine and Gemcitabine Study

AEterna Zentaris

Phase 1 Completed
19 enrolled
Tumor-Agnostic

Neoplasms

NCT00399087 2014-02-13

Phase I Trial of Docetaxel With Perifosine

AEterna Zentaris

Phase 1 Completed
39 enrolled
Tumor-Agnostic

Neoplasms

NCT00399126 2014-02-13

Phase I Trial of Paclitaxel With Perifosine

AEterna Zentaris

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡